SII to Manufacture Oxford's Ebola Vaccine with CEPI Funding Amid Outbreak

The Serum Institute of India (SII), recognized as the world's largest vaccine manufacturer, has entered a crucial partnership with the University of Oxford to produce clinical trial doses of an experimental vaccine designed to combat the Bundibugyo strain of the Ebola virus. This expedited effort is financially bolstered by the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed initial funding of up to US$8.6 million. The primary goal of this collaboration is to accelerate the development and manufacturing of a vaccine in response to a rapidly escalating Ebola outbreak in the Democratic Republic of Congo (DRC) and neighboring Uganda. The ongoing Bundibugyo ebolavirus outbreak has been officially declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) and a Public Health Emergency of Continental Security (PHECS) by the Africa Centres for Disease Control and Prevention (Africa CDC). This classification underscores the severity and urgency of the situation, with reports indicating hundreds of suspected cases and fatalities. There are currently no licensed vaccines or specific treatments available for the Bundibugyo strain, highlighting the critical need for new interventions. Oxford University's vaccine candidate, known as ChAdOx1 BDBV, is built upon the well-established ChAdOx1 viral-vector platform. This is the same innovative technology that successfully underpinned the Oxford-AstraZeneca COVID-19 vaccine, widely distributed globally, including by SII as Covishield. The proven efficacy and safety profile of the ChAdOx1 platform, combined with existing manufacturing infrastructure and expertise at SII, are expected to significantly expedite the development process. CEPI's funding, amounting to US$8.6 million, will specifically support preclinical testing, crucial development activities, and the preparation required for Phase 1 clinical trials. A key aspect of this funding is also to facilitate the creation of a Master Virus Seed stock and the manufacturing of clinical-grade doses at SII, leveraging CEPI's pre-existing agreements with the company and its Vaccine Manufacturing Facility Network. This strategic partnership aims to ensure that once the vaccine proves safe and effective in initial human testing, large-scale production can commence rapidly to ensure equitable access in affected regions. Professor Teresa Lambe, Head of Vaccine Immunology at the Oxford Vaccine Group, Pandemic Sciences Institute, University of Oxford, emphasized the rapid progress, stating that animal studies for the Oxford vaccine candidate are already underway. She expressed optimism about having clinical-grade vaccine doses ready within two to three months, attributing this speed to SII's proven manufacturing capabilities. Adar Poonawalla, CEO of the Serum Institute of India, reiterated SII's commitment, highlighting the importance of "speed, scale and access" in such critical moments and confirming SII's readiness to leverage its manufacturing prowess for this collaboration. This initiative is part of a broader, concerted effort by CEPI to accelerate the development of multiple investigational vaccines against the Bundibugyo strain. In total, CEPI is investing approximately US$60 million across three promising candidates. Besides the Oxford-SII vaccine, Moderna has received up to US$50 million to advance its mRNA-based vaccine candidate, and the International AIDS Vaccine Initiative (IAVI) has been awarded US$3.2 million for its rVSV platform-based candidate. This multi-platform approach is designed to maximize the chances of successfully developing a safe and effective vaccine for this specific Ebola strain. The collaboration signifies India's growing role in global health security, demonstrating its capacity to contribute to urgent international public health needs. SII's extensive experience from its previous work on the COVID-19 vaccine, where it rapidly scaled up production of Covishield, positions it as a vital partner in this global endeavor. The ability to quickly produce clinical trial doses is crucial for initiating human trials and, if successful, for making the vaccine available to vulnerable populations in Africa as swiftly as possible. This robust partnership between academic research, global funding bodies, and leading manufacturers is a testament to the collaborative spirit required to tackle emerging infectious disease threats worldwide. The news also aligns with previous reports from NDTV highlighting the intensification of the Ebola vaccine race, confirming that global efforts are indeed surging to find solutions for this deadly disease. The rapid response by CEPI and its partners underscores the lessons learned from previous pandemics, emphasizing proactive preparedness and accelerated vaccine development to contain outbreaks before they escalate further. The hope is that through these concerted efforts, effective vaccines can be developed and deployed to control the current Bundibugyo outbreak and strengthen global readiness for future threats.

Frequently Asked Questions

Read Full Story on Quick Digest